Page last updated: 2024-09-05

sorafenib and tandutinib

sorafenib has been researched along with tandutinib in 12 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(tandutinib)
Trials
(tandutinib)
Recent Studies (post-2010) (tandutinib)
6,5207305,25169541

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)tandutinib (IC50)
Integrin beta-3Homo sapiens (human)0.22
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)3.43
Integrin alpha-IIbHomo sapiens (human)0.22
Platelet-derived growth factor receptor betaHomo sapiens (human)0.149
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1867
Fibroblast growth factor receptor 1Homo sapiens (human)0.17
Cannabinoid receptor 1Rattus norvegicus (Norway rat)0.2
Fibroblast growth factor receptor 2Homo sapiens (human)0.17
Fibroblast growth factor receptor 4Homo sapiens (human)0.17
Fibroblast growth factor receptor 3Homo sapiens (human)0.17
Vascular endothelial growth factor receptor 2Homo sapiens (human)2.07
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.9345
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.2
Cannabinoid receptor 2Rattus norvegicus (Norway rat)0.2

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's8 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP1
Chang, CN; Chen, CH; Chen, GS; Chen, YC; Chern, JW; Chou, NT; Chou, SH; Hseu, TH; Hsu, HC; Hu, TL; Huang, CH; Hwang, CS; Khanwelkar, RR; Ko, CH; Lee, O; Lin, HC; Lin, MW; Liu, CP; Shih, YC; Tsai, YJ; Tseng, HW; Tu, CM; Wang, HC; Wang, LM; Yu, CW1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Ehninger, G; Illmer, T1
Atrash, B; Avery, S; Bavetsias, V; Blagg, J; de Haven Brandon, A; Eccles, SA; Faisal, A; Gonzalez de Castro, D; Linardopoulos, S; Mair, D; Mirabella, F; Moore, AS; Pearson, AD; Raynaud, FI; Sun, C; Swansbury, J; Valenti, M; Workman, P1
Hu, B; Mohty, M; Savani, BN; Vikas, P1

Reviews

2 review(s) available for sorafenib and tandutinib

ArticleYear
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
    Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1

    Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib

2007
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
    Expert review of hematology, 2014, Volume: 7, Issue:2

    Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous

2014

Other Studies

10 other study(ies) available for sorafenib and tandutinib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
    Blood, 2009, Oct-01, Volume: 114, Issue:14

    Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays

2009
Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.
    Bioorganic & medicinal chemistry, 2010, Jul-01, Volume: 18, Issue:13

    Topics: Animals; Aurora Kinases; Binding Sites; Cell Line, Tumor; Computer Simulation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Indoles; Leukemia, Myeloid; Mice; Oxindoles; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship; Transplantation, Heterologous; Urea

2010
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Leukemia, 2012, Volume: 26, Issue:7

    Topics: Animals; Apoptosis; Aurora Kinases; Benzenesulfonates; Benzothiazoles; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Quinazolines; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured

2012